.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,375,082

« Back to Dashboard

Details for Patent: 7,375,082

Title:Abuse-resistant hydrocodone compounds
Abstract: The present invention decreases the potential for abuse of opioids, particularly hydrocodone, by covalent modification. The invention provides methods of delivering hydrocodone as conjugates that release the hydrocodone following oral administration while being resistant to abuse by circuitous routes such as intravenous ("shooting") injection and intranasal administration ("snorting"). Further, hydrocodone compositions of the invention are resistant to oral abuse as well, since release of the hydrocodone at suprapharmacological doses reaches saturation.
Inventor(s): Mickle; Travis (Charlottesville, VA), Krishnan; Suma (Blacksburg, VA), Moncrief; James Scott (Christiansburg, VA), Mickle; Christal (Charlottesville, VA), Lauderback; Christopher (Blacksburg, VA), Piccariello; Thomas (Blacksburg, VA)
Assignee: Shire LLC (Florence, KY)
Filing Date:Sep 30, 2004
Application Number:10/953,116
Claims:1. A composition comprising hydrocodone covalently bound at the 6' position to a single amino acid or an oligopeptide of 15 or fewer amino acids through the N-terminus or side chain of said oligopeptide or said amino acid, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive in a form suitable for oral administration.

2. The composition of claim 1, wherein said oligopeptide comprises fewer than 10 amino acids.

3. The composition of claim 1, wherein said oligopeptide comprises fewer than 6 amino acids.

4. The composition of claim 1, wherein the oligopeptide is selected from a dipeptide, a tripeptide, a tetrapeptide, a pentapeptide, and a hexapeptide.

5. The composition of claim 1, wherein the oligopeptide is a pentapeptide.

6. The composition of claim 5, wherein said pentapeptide consists essentially of naturally occurring amino acids.

7. The composition of claim 1 wherein said hydrocodone is resistant to release from said amino acid or said oligopeptide when the composition is manipulated for parenteral administration.

8. The composition of claim 1, wherein said form suitable for oral administration is a tablet, a capsule, a caplet, an oral solution, or an oral suspension.

9. The composition of claim 6, wherein said form suitable for oral administration is a tablet, a capsule, a caplet, an oral solution, or an oral suspension.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc